NCT00035282
Completed
Phase 3
A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Major Depressive Disorder
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 450
- Primary Endpoint
- HAMD-17 total score at week 8. Tolerability.
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
Detailed Description
The duration of treatment is 8 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
HAMD-17 total score at week 8. Tolerability.
Time Frame: at week 8
Secondary Outcomes
- CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8(at week 8)
Similar Trials
Completed
Phase 3
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive DisorderNCT00048594Merck Sharp & Dohme LLC800
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)Major Depressive DisorderNCT00035048Merck Sharp & Dohme LLC540
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)Major Depressive DisorderNCT00034983Merck Sharp & Dohme LLC900
Completed
Phase 2
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe PsoriasisModerate to Severe Chronic Plaque PsoriasisNCT00601107Genzyme, a Sanofi Company111
Completed
Phase 3
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)Prostate CancerNCT00060476Merck Sharp & Dohme LLC15,000